Unlike urothelial cancer, which has a high rate of FGFR3 mutations, cholangiocarcinoma harbours an increased frequency of fusions or rearrangements that favour FGFR2 and a diverse group of partner genes. The gene discussed is FGFR3; the disease is cholangiocarcinoma.